Search results
Results from the WOW.Com Content Network
This page lists cancer drugs approved by the Food and Drug Administration (FDA) for bladder cancer. The list includes generic names, brand names, and common drug combinations, which are shown in capital letters.
In 2023, the Food and Drug Administration (FDA) approved a two-drug combination of enfortumab vedotin and pembrolizumab (EV/pembro) to treat locally advanced or metastatic urothelial bladder cancer.
One treatment—the combination of enfortumab vedotin (Padcev) and the immunotherapy drug pembrolizumab (Keytruda)—proved to be particularly powerful. The findings mark a pivotal moment following years of little progress, according to several leading bladder cancer experts.
The U.S. Food and Drug Administration (FDA) on April 3 approved enfortumab vedotin (Padcev®) plus the immunotherapy drug pembrolizumab (Keytruda®) for people newly diagnosed with metastatic urothelial carcinoma — a cancer that primarily arises in the bladder and also occurs in other parts of the urinary system.
The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma. This is the first product in its...
Platinum-containing chemotherapy, PD-1 and PD-L1 inhibitors are standard treatments for patients with bladder cancer, the sixth most common cancer in the U.S. Urothelial cancer,...
The aims of this review are to discuss these newly approved agents for bladder cancer and to feature promising drugs and combinations—including immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates—that are in development.
Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk muscle-invasive bladder cancer are cancer-free following surgical removal of the bladder.
Since 2016, four checkpoint inhibitor drugs have been approved for bladder cancer: atezolizumab (Tecentriq®), pembrolizumab (Keytruda®), nivolumab (Opdivo®), and avelumab (Bavencio®). The drugs target molecules called PD-1 or PD-L1, which are on the surface of immune T cells or on cancer cells.
FRIDAY, April 26, 2024 -- The U.S. Food and Drug Administration has approved Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, with or without papillary tumors.